Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors. (February 2020)

• Record Type: Journal Article
• Authors: Romero, Sally A.D.; Su, H. Irene; Satagopan, Jaya; Li, Q. Susan; Seluzicki, Christina M.; Dries, Annika; DeMichele, Angela M.; Mao, Jun J.
• Is Part Of: Breast. Volume 49(2020)
• Page Start: 48
• Page End: 54
• Publication Date: 2020-02
• Subjects: Breast neoplasm -- Aromatase inhibitor -- Genetics -- Arthralgia -- Postmenopausal -- Risk factors; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2019.10.008
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: Background: Arthralgia is a common and debilitating toxicity of aromatase inhibitors (AI) that leads to premature drug discontinuation. We sought to evaluate the clinical and genetic risk factors associated with AI-associated arthralgia (AIAA). Methods: We performed a cross-sectional study among postmenopausal women with stage 0-III breast cancer who were prescribed a third-generation AI for adjuvant therapy. The primary outcome was patient-reported AIAA occurrence. We extracted and assayed germline DNA for single nucleotide polymorphisms (SNPs) of genes implicated in estrogen and inflammation pathways. Multivariable logistic regression models examined the association between demographic, clinical, and genetic factors and AIAA. Analyses were restricted to White participants. Results: Among 1049 White participants, 543 (52%) reported AIAA. In multivariable analyses, women who had a college education [Adjusted Odds Ratio (AOR) 1.49, 95% Confidence Interval (CI) 1.00–2.20], had a more recent transition into menopause (<10 years) (5–10 years AOR 1.55, 95% CI 1.09–2.22; <5 years AOR 1.78, 95% CI 1.18–2.67), were within one year of starting AIs (AOR 1.61, 95% CI 1.08–2.40), and those who received chemotherapy (AOR 1.38, 95% CI 1.02–1.88) were significantly more likely to report AIAA. Additionally, SNP rs11648233 ( HSD17B2 ) was significantly associated with higher odds of AIAA (AOR 2.21, 95% CI 1.55–3.16). Conclusions: Time since menopause and start of AIs, prior chemotherapy, and SNP rs11648233 within the HSD17B2 gene in the estrogen pathway were significantly associated with patient-reported AIAA. These findings suggest that clinical and genetic factors involved in estrogen withdrawal increase the risk of AIAA in postmenopausal breast cancer survivors. Highlights: One in two postmenopausal women experience aromatase inhibitor-associated arthralgia. Shorter time since starting menopause and aromatase inhibitors are clinical risk factors for AIAA. SNP rs11648233 ( HSD17B2 ) in the estrogen pathway may contribute to AIAA.